Clinical trial
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB…
NCT00098332 · BioCryst Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00098332 |
|---|---|
| Title | Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma |
| Official title | A Phase I, Multi-Center, Open-Label, Safety and Pharmacokinetic, Repeat-Dose Study of Oral Forodesine Hydrochloride in Patients With Refractory Cutaneous T-Cell Lymphoma |
| Lead sponsor | BioCryst Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | forodesine hydrochloride |
| Start date | Nov 1, 2004 |
| Primary completion | Dec 1, 2010 |
| Completion | Jul 1, 2011 |
| First posted | Dec 8, 2004 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: